ScholarIQanswers from OpenAlex & ORCID
Danny Rischin
ResearcherPublications, citations & collaboration network
Danny Rischin is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Danny Rischin have?
ScholarIQindexed works
Danny Rischin has 745 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Danny Rischin have?
ScholarIQcitation count
Danny Rischin has 32,624 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Danny Rischin?
ScholarIQh-index
Danny Rischin has an h-index of 75 in OpenAlex.
What is the i10-index of Danny Rischin?
ScholarIQi10-index
Danny Rischin has an i10-index of 264 in OpenAlex.
What is the ORCID of Danny Rischin?
ScholarIQorcid
The ORCID for Danny Rischin is on the source record.
What is the OpenAlex record for Danny Rischin?
ScholarIQopenalex
The OpenAlex for Danny Rischin is on the source record.
What are the most-cited papers on Danny Rischin?
ScholarIQmost cited works
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness, Kevin J. Harrington, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Neus Basté, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett Hughes, Ricard Mesı́a, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Ruey‐Long Hong, René González Mendoza, Ananya Roy, Yayan Zhang, Burak Gümüşçü, Jonathan D. Cheng, Fan Jin, Danny Rischin, Guillermo Lerzo, Marcelo Tatangelo, Mirta Varela, Juan José Zarbá, Michael Boyer, Hui Gan, Bo Gao, Brett Hughes, Girish Mallesara, Danny Rischin, Anne L. Taylor, Martin Burian, Thorsten Fuereder, Richard Greil, Carlos H. Barrios, Dalvaro Oliveira de Castro Junior, Gilberto de Castro, Fábio Franke, Gustavo Girotto, Iane Pinto Figueiredo Lima, Ulisses Ribaldo Nicolau, Gustavo Dix Junqueira Pinto, Lucas Vieira dos Santos, Ana-Paula Victorino, Neil Chua, Félix Couture, Richard Gregg, Aaron R. Hansen, John Hilton, Joy McCarthy, Denis Soulières, Rodrigo Ascuí, Pablo Gonzalez, Luis J. Villanueva-Rivera, Marco Torregroza, Ángela R. Zambrano, Petra Holečková, Zdeněk Král, Bohuslav Melichar, Prausova Jana, Milan Vošmik, Maria Andersen, Niels Gyldenkerne, Hannes Jürgens, Kadri Putnik, Petri Reinikainen, Viktor Gruenwald, Simon Laban, Gerasimos Aravantinos, Ioannis Boukovinas, Vassilis Georgoulias, Amanda Psyrri, D.L.W. Kwong, Yousuf Al-Farhat, Tibor Csőszi, József Erfán, Geza Horvai, László Landherr, Éva Remenár, Ágnes Ruzsa, Judit Szota, Salem Billan, Iris Gluck, Orit Gutfeld, Aron Popovtzer, Marco Benasso, Simona Bui, Vittorio Ferrari, Lisa Licitra, Franco Nolè, Takashi Fujii, Yasushi Fujimoto, Nobuhiro Hanai, Hiroki Hara, Koji Matsumoto, Kenji Mitsugi
Prognostic Significance of [<sup>18</sup>F]-Misonidazole Positron Emission Tomography–Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer Randomly Assigned to Chemoradiation With or Without Tirapazamine: A Substudy of Trans-Tasman Radiation Oncology Group Study 98.02
Danny Rischin, Rodney J. Hicks, Richard Fisher, David Binns, June Corry, Sandro Porceddu, Lester J. Peters
Positron Emission Tomography Is Superior to Computed Tomography Scanning for Response-Assessment After Radical Radiotherapy or Chemoradiotherapy in Patients With Non–Small-Cell Lung Cancer
Michael P. Mac Manus, Rodney J. Hicks, Jane Matthews, Allan McKenzie, Danny Rischin, Eeva Salminen, David Ball
F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma
Michael P. Mac Manus, Rodney J. Hicks, David Ball, Victor Kalff, Jane Matthews, Eeva Salminen, Pearly Khaw, Andrew Wirth, Danny Rischin, A L McKenzie